AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for its blockbuster drug, Humira, in the United States in January 2023 and in the EU in 2018. Humira's sales are ...

AbbVie's rheumatoid arthritis blockbuster Humira is set for $15 billion in revenues this year, but the first biosimilars could be on the US market as early as next year. The US company had pinned ...

AbbVie’s executives, perhaps guided by previously slow biosimilar adoption in Europe, have forecast a drop of Humira sales in Europe of only around 18 to 20%, by the end of next year.

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?